

PRESS BOOK

Preclinical Research Papers and Posters

A GLOBAL SERVICE PROVIDER OF PRECLINICAL AND CLINICAL RESEARCH IN OPHTHALMOLOGY



Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model #2022-250

SCHUBERT W (a), TERJUNG C (a), RAFIQUE A (b), ROMANO C (b), ELLINGER P (a), RITTENHOUSE K (c)
Trans. Vis. Sci. Tech. 2022;11(10):36. doi: 10.1167/tvst.11.10.36 (collaboration)

(a) BAYER AG, Wuppertal, Germany – (b) REGGENERON PHARMACEUTICALS, Inc., Tarrytown, NY, USA – (c) BAYER CONSUMER CARE AG, Basel, Switzerland



Successful Proof-of-Concept for Topical Delivery of Novel Peptide ALM201 with Potential Usefulness for Treating Neovascular Eye Disorders #2022-246

OBASANMI G (a), NESBIT MA (a), COBICE D (a), MACKAY L (b), MCGIMPSEY S (c), WAPPETT M (d), CRANSTON AN (d), MOORE TCB (a)

Ophthalmol. Sci. 2022; 2, 2, 100150. https://doi.org/10.1016/j.xops.2022.100150 (collaboration)

(a) BIOMEDICAL SCIENCES RESEARCH INSTITUTE, Ulster University, Coleraine, United Kingdom - (b) Scottish Instrumentation and Research Centre for Advanced Mass Spectrometry (SIRCAMS), University of Edinburgh, Edinburgh, United Kingdom - (c) Mater Infirmitorum Hospital, Belfast, United Kingdom - (d) ALMAC DISCOVERY Ltd., Belfast, United Kingdom



New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma #2022-245

ALVISET G (a),(b),(c), CORVIS Y (b), HAMMAD K (d), LEMUT J (e),(f), MAURY M (f), MIGNET N (b), BOUDY V (b),(c)
Pharmaceutics 2022, 14, 453. https://doi.org/10.3390/pharmaceutics14020453 (collaboration)

(a) UNITHER Développement Bordeaux, Le Haillan, France – (b) CNRS, INSERM, UTCBS, Paris, France - (c) Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France – (d) CNRS, CiTCoM, Paris, France – (e) CMC Expert, Montpellier, France – (f) UNITHER PHARMACEUTICALS, Paris, France



A comparative pharmacokinetics study of 3 Latanoprost eyedrops solutions containing various excipients in an animal model #2022-244

REBIKA H (a),(c), CHAUCHAT L (a), AMAR T (b), VIAUD-QUENTRIC K (b), GUERIN C (a)
ARVO meeting 2022; Denver, CO - USA. Abstract No. 4166 – F0158

Invest. Ophthalmol. Vis. Sci. 2022;63(7):4166 – F0158.

(a) HORUS PHARMA, Saint Laurent du Var, France – (b) IRIS PHARMA, La Gaude, France – (c) Centre Hospitalier Universitaire de Clermont-Ferrand, France



Comparison of two experimental mouse dry eye models through inflammatory gene set enrichment analysis based on a multiplexed transcriptomic approach #2021-243

KESSAL K (a),(b),(c), DAULL P (d), CIMBOLINI N (e), FERAILLE L (e), GRILLO S (e), DOCQUIER M (f), BAUDOIN C (a),(b),(c),(g), BRIGNOLE-BAUDOIN F (a),(b),(c),(h), GARRIGUE JS (d)

Int. J. Mol. Sci. 2021; 22, 10770. https://doi.org/10.3390/ijms221910770

(a) INSERM UMR 968, CNRS UMR 7210, Institut de la Vision, IHU ForSight, Sorbonne Université UM80, Paris, France - (b) Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-DGOS CIC1423, IHU FOReSIGHT, Paris, France - (c) Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France - (d) SANTEN SAS, Evry, France - (e) IRIS PHARMA, La Gaude, France - (f) iGE3 Genomics Platform, University of Geneva, Geneva, Switzerland - (g) Ambroise Paré, APHP, Department of Ophthalmology, University Paris Saclay, Boulogne, France - (h) Faculté de Pharmacie, Université de Paris, Paris, France



Assessment of a New Nanostructured Microemulsion System for Ocular Delivery of Sorafenib to Posterior Segment of the Eye #2021-240

SANTONOCITO M (a), ZAPPULLA C (a), VIOLA S (a), LA ROSA LR (a), SOLFATO E (a), ABBATE I (a), TARALLO V (b), APICELLA I (b), PLATANIA CBM (c), MAUGERI G (c), D'AGATA V (c), BUCOLO C (c), DE FALCO S (b), MAZZONE MG (a), GIULIANO F (a)

Int. J. Mol. Sci. 2021; 22, 4404. https://doi.org/10.3390/ijms22094404 (collaboration)

(a) SIFI S.p.A., Catania, Italy - (b) Institute of Genetics and Biophysics, CNR, Napoli, Italy - (c) Department of Biomedical and Biotechnological Sciences, University of Catania, Italy



Review of Preclinical Outcomes of a Topical Cationic Emulsion of Cyclosporine A for the Treatment of Ocular Surface Diseases #2021-239

DAULL P (a), BAUDOIN C (b), LIANG H (c), FERAILLE L (d), BARABINO S (e), GARRIGUE JS (a)
Ocul. Immunol. Inflamm. 2021; Aug 4; 1-11. doi: 10.1080/09273948.2021.1957124

(a) SANTEN SAS, Evry, France - (b) CHNO des Quinze-Vingts, IHU FOReSIGHT, INSERM-DGOS CIC 1423, Paris, France - (c) Sorbonne Universités, INSERM, CNRS, Institut de la Vision, Paris, France - (d) IRIS PHARMA, La Gaude, France - (e) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy



MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment#2021-238

ENTCHEV E (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), JANTZEN I (a), ROUSSEY A (a), GERMAIN JM (a), ZHANG H (c), LUCCARRINI JM (a), LACOMBE O (a), YOUNG S (c)(d), FERAILLE L (b), TALLANDIER M (a)

Mol. Genet. Metab. 2021; doi: 10.1016/j.ymgme.2021.07.008 (pre-print on July 25, 2021)

(a) INVENTIVA PHARMA, Daix, France - (b) IRIS PHARMA, La Gaudé, France - (c) DUKE UNIVERSITY HEALTH SYSTEM BIOCHEMICAL GENETICS LAB, Durham, NC, USA - (d) DUKE SCHOOL OF MEDICINE, Durham, NC, USA



A rare natural lipid induces neuroglobin expression to prevent amyloid oligomers toxicity and retinal neurodegeneration#2021-237

OAMEN HP (a), ROMERO N (a), KNUCKLES P (b), SAARIKANGAS J (c), DONG Y (d), CAUDRON F (a)
doi: 10.1101/2021.06.23.449608 (pre-print on June 23, 2021) (collaboration)

(a) SCHOOL OF BIOLOGICAL SCIENCES, London, UK - (b) FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) HELSINKI INSTITUTE OF LIFE SCIENCE, Helsinki, Finland; UNIVERSITY OF HELSINKI, Finland - (d) SUNREGEN HEALTHCARE AG, Reinach, Switzerland



Ocular surface response of two preservative-free cyclosporine A emulsion eye drops in a mouse model of dry eye#2021-236

DAULL P (a), NAGANO T (b), GROS E (c), FERAILLE L (c), BARABINO S (d), GARRIGUE JS (a)
Curr. Eye Res. 2021. doi: 10.1080/02713683.2021.1878228

(a) SANTEN SAS, Evry, France - (b) SANTEN Pharmaceutical Co., Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaudé, France - (d) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy



DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously#2021-235

BECKMANN R (a), JENSEN K (a), FENN S (a) et al.
Nature 2021; 12, 708. doi: 10.1038/s41467-021-20949-3 (collaboration)

(a) ROCHE PHARMA Research and Early Development, Penzberg, Germany



Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB-VCAM-1 axis#2020-231

Y LI (a), A ALHENDI (a), MC YEH (a), M ELAHY (a), F SANTIAGO (a), N DESHPANDE (b), B WU (a), E CHAN (a), S INAM (a), L PRADO-LOURENCO (a), J MARCHAND (c), R JOYCE (c), L WILKINSON-WHITE (d), M RAFTERY (e), M ZHU (f,g,h), S ADAMSON (h), F BARNAT (i), K VIAUD-QUENTRIC (i), J SOCKLER (j), J MACKAY (k), A CHANG (g,h,l), P MITCHELL (m), S MARCUCCIO (c,n), L KHACHIGIAN (a)

Sci. Adv. 2020; 6 : eaaz7815 DOI: 10.1126/sciadv.aaz7815

(a) Vascular Biology and Translational Research, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia (b) Systems Biology Initiative, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (c) ADVANCED MOLECULAR TECHNOLOGIES Pty Ltd, Scoresby, Australia – (d) Sydney Analytical Core Facility, UNIVERSITY OF SYDNEY, Australia – (e) Bioanalytical Mass Spectrometry Facility, UNIVERSITY OF NEW SOUTH WALES, Sydney, Australia – (f) New South Wales Tissue Bank, Kogarah, Australia – (g) SAVE SIGHT INSTITUTE, University of Sydney, Australia – (h) GREENLIGHT CLINICAL Pty. Ltd., Woolloomooloo, Australia – (i) IRIS PHARMA, La Gaudé, France – (j) DATAPHARM AUSTRALIA Pty. Ltd., Drummoyne, Australia – (k) School of Life and Environmental Sciences, UNIVERSITY OF SYDNEY, Australia – (l) SYDNEY EYE HOSPITAL, Australia – (m) Centre for Vision Research, WESTMEAD INSTITUTE OF MEDICAL RESEARCH, Westmead, Australia – (n) LA TROBE INSTITUTE FOR MOLECULAR SCIENCE, Melbourne, Australia



SBC003 demonstrates neuroprotective effects in a murine model of N-nitroso-N-methylurea (NNU) induced photoreceptor degeneration#2020-230

DONG Y (a), HARKIN K (b), FERAILLE L (c), CHEN M (b), XU H (b)

Invest. Ophthalmol. Vis. Sci. 2020; 61(7):2475.

(a) SUNREGEN HEALTHCARE AG, Allschwil, Switzerland - (b) QUEEN'S UNIVERSITY BELFAST, United Kingdom - (c) IRIS PHARMA, La Gaudé, France



The uni-nephrectomized and salt-loaded SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy#2020-229

SHINOHARA M (a), BRIAND F (b), ANTONELLI S (c), MAURO V (c), CIMBOLINI N (c), BROUSSEAU E (b), OHTA T (d), MIYAJIMA K (e), KAGEYAMA Y (a), FERAILLE L (c), SULPICE T (b)

Japanese Society of Toxicologic Pathology meeting 2020; Tokuo, JAPAN

(a) CLEA Japan Inc., Tokyo, Japan - (b) PHYSIOGENEX, Labège, France - (c) IRIS PHARMA, La Gaudé, France - (d) Kyoto University, Kyoto, Japan - (e) Tokyo University of Agriculture, Tokyo, Japan



The potential effect of human chorionic gonadotropin on vasoproliferative disorders of the immature retina#2019-247

MOVSAS TZ (a), MUTHUSAMY A (b) (collaboration)

Neuroreport. 2018; 29:18, 1525-1529. doi: 10.1097/WNR.0000000000001140 (collaboration)

(a) ZIETCHICK RESEARCH INSTITUTE, Plymouth, MI, USA - (b) Michigan State University, East Lansing, MI, USA



Modulation of inflammation-related genes in the cornea of a mouse model of dry eye upon treatment with cyclosporine eye drops#2019-222

DAULL P (a), BARABINO S (b), **FERAILLE L** (c), KESSAL K (d), DOCQUIER (e), PARSAADIANTZ S (d), BAUDOUIN C (d,f), GARRIGUE JS (a)

Curr. Eye Res. 2019; Jan 21:1-10. doi: 10.1080/02713683.2018.1563197

(a) SANTEN SAS, Evry, France - (b) OCULAR SURFACE & DRY EYE CENTER, University of Milan, Italy - (c) IRIS PHARMA, La Gaude, France - (d) INSTITUT DE LA VISION, Paris, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) Quinze-Vingts National Ophthalmology Hospital, Paris, France



Chronic model of uveitis in rabbit - Efficacy of triamcinolone acetonide#2019-221

QUENTRIC Y (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), **FERAILLE L** (a), ELENA PP (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 800 - B0278

(a) IRIS PHARMA, La Gaude, France



Efficacy of preservative-free cyclosporine emulsion eye drops in a mouse model of dry eye#2019-220

DAULL P (a), NAGANO T (b), OKADA S (b), GROS E (c), **FERAILLE L** (c), GARRIGUE JS (a)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 292 - B0431

(a) SANTEN SAS, Evry, France - (b) SANTEN Ltd., Osaka, Japan - (c) IRIS PHARMA, La Gaude, France



Dry Eye: efficacy evaluation of two synthetic peptides from chondrocyte derived extracellular matrix (CDEM) in comparison to lifitegrast, cyclosporine A, diquafosol sodium and sodium hyaluronate in a murine model of dry eye#2019-219

BAIK T (a), CHOI J (a), MIN K (a), **FERAILLE L** (b), RAYMOND E (b), ELENA PP (b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 291 - B0430

(a) YUYU PHARMA, Seoul, The Republic of Korea - (b) IRIS PHARMA, La Gaude, France



Comparison of inflammatory gene networks in dry eye between human and mouse#2019-218

KESSL K (a,b), DAULL P (c), **FERAILLE L** (d), CIMBOLINI N (d), LIANG H (a,b), DOCQUIER (e), BARABINO S (f), MELIK PARSAADIANTZ S (a), GARRIGUE JS (c), BAUDOUIN C (a,b), BAUDOUIN F (a,b)

ARVO meeting 2019; Vancouver - CANADA. Abstract No. 274 - B0413

(a) INSTITUT DE LA VISION, Paris, France - (b) Quinze-Vingts National Ophthalmology Hospital, Paris, France - (c) SANTEN SAS, Evry, France - (d) IRIS PHARMA, La Gaude, France - (e) iGE3 Genomics Platform, University of Geneva, Switzerland - (f) CLINICA OCULISTICA, Genova, Italy



Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits#2018-241

DAHMANA N (a), MUGNIER T (b), GABRIEL D (b), KALTSATOS V (c), BERTAIM T (c), BEHAR-COHEN F (d,e), GURNY R (a,b), KALIA Y (a) (collaboration)

Mol Pharm. 2018 Mar 5;15(3):1192-1202. doi: 10.1021/acs.molpharmaceut.7b01028

(a) University of Geneva & University of Lausanne, Geneva, Switzerland – (b) APIDEL SA, Geneva, Switzerland – (c) CEVA Santé Animal, Libourne, France – (d) Fondation Asile des Aveugles, Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland – (e) INSERM, UMRS 872 Team 17, Paris, France



Safety and tolerability of overdosed artificial tears by abraded rabbit corneas#2018-215

DAULL P (a), RAYMOND E (b), **FERAILLE L** (b), GARRIGUE JS (a)

J. Ocul. Pharmacol. Ther. 2018; DOI: 10.1089/jop.2018.0040

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



The uni-nephrectomized SDT fatty rat, a novel type 2 diabetic model of diabetic nephropathy, develops features of diabetic retinopathy over 10 weeks#2018-214

BRIAND F (a), ANTONELLI S (b), MAURO V (b), CIMBOLINI N (b), SHINOHARA M (c), BROUSSEAU E (a), OHTA T (d), KAGEYAMA Y (c), **FERAILLE L** (b), SULPICE T (a)

ARVO meeting 2018; Hawaii - USA. Abstract No. 3573 - A0190

(a) PHYSIOGENEX, Labege, France - (b) IRIS PHARMA, La Gaude, France - (c) CLEA Japan Inc., Tokyo, Japan - (d) JAPAN TOBACCO Inc., Osaka, Japan



Ocular tolerance in rabbits after intracameral administration of a fixed combination of tropicamide, phenylephrine, and lidocaine with and without rinsing#2017-227

NUIJTS R (a), MENCUCCI R (b), VIAUD-QUENTRIC K (c), ELENA PP (c), OLMIERE C (d), BEHNDIG A (e)

J. Cataract Refr. Surg. 2017; 43: 673-679. DOI: 10.1016/j.jcrs.2017.03.025

(a) Maastricht Universitair Medisch Centrum, the Netherlands – (b) University of Florence, Italy – (c) IRIS PHARMA, La Gaude, France – (d) LABORATOIRES THEA, Clermont-Ferrand, France – (e) Umeå University, Sweden



Exploratory ocular surface distribution studies of azithromycin formulations based on semifluorinated alkanes#2017-213

FISCHER K (a), GRILLENBERGER R (a), AMAR T (b), KRÖSSER S (a)

EVER meeting 2017; Nice, France. Acta Ophthalmologica. DOI: 10.1111/j.1755-3768.2017.0S029

(a) NOVALIQ GmbH, 69120 Heidelberg, Germany - (b) IRIS PHARMA, La Gaude, France



Oral administration of the 11 β -hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study#2017-212

SCHWAB D (a), STURM C (a), PORTRON A (a), FUERST-RECKTENWALD S (b), HAINZL D (c), JORDAN P (d), STEWART W (e), TEPEDINO M (f), DUBINER H (g)

BMJ Open Ophth 2017;1:e000063. DOI: 10.1136/bmjophth-2016-000063 (collaboration)

(a) ROCHE INNOVATION CENTER, Clinical Pharmacology, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (b) ROCHE INNOVATION CENTER, Translational Medicine, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (c) ROCHE INNOVATION CENTER, Pharmaceutical Sciences, Roche Pharmaceutical Research and Early Development, Basel, Switzerland (d) Department of Biometrics, Product development, Roche Pharmaceutical Research and Early Development, Basel, Switzerland - (e) PRN Pharmaceutical Research Network, LLC, Cheyenne, Wyoming, USA - (f) Cornerstone Eye Care, Division of Health Care, High Point, North Carolina, USA - (g) Eye Care Centers Management, Inc., Clayton Eye Center, Morrow, Georgia, USA

Transform your macroscope into an ultramacroscope for 3D imaging of cleared organs#2017-211

GESSION M (a), KECHAD M (b), MAUCLERT N (c), GIRARD P (c), ROUSSEL A (c), PIERRE O (d), GROSJEAN I (e), BRAU F (f)
Focus on Microscopy meeting 2017; Bordeaux - France. Poster No P2-A/26

(a) CNRS, INSERM, Institut Biologie Valrose, Nice, France - (b) IRIS PHARMA, La Gaude, France - (c) OCA, Service de Mécanique Mutualisé, France - (d) IINRA, Institut Sophia Agrobiotech, Biot, France - (e) INSERM, Institut de Recherche sur le Cancer et le Vieillissement, Nice, France - (f) CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, Valbonne, France

Comparative efficacy of preservative-free anti-inflammatory eye drops in a mouse model of dry eye#2017-210

GARRIGUE JS (a), CIMBOLINI N (b), KESSAL K (c), GROS E (b), MAURO V (b), BARABINO S (d), BAUDOUIN C (c), DAULL P (a)
ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 800. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

Conditional self-knockout of otx2 mice: a new model for late-onset neuronal degeneration#2017-209

ELENA PP (a), ANTONELLI S (a), MAURO V (a), CIMBOLINI N (a), LAMONERIE T (b), FERAILLE L (a)
ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 4532 - Poster B0187

(a) IRIS PHARMA, La Gaude, France - (b) UNIVERSITE DE NICE, Nice, France

Corneal transcriptome changes in a mouse model of dry eye#2017-208

DAULL P (a), FERAILLE L (b), KESSAL K (c), ELENA PP (b), BARABINO S (d), BAUDOUIN C (c), GARRIGUE JS (a)
ARVO meeting 2017; Baltimore - USA. Invest. Ophthalmol. Vis. Sci. 2017; 58(8): 797. doi:

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) INSTITUT DE LA VISION, Paris, France - (d) CLINICA OCULISTICA, Genoa, Italy

Safety evaluation of cationic emulsions following refractive surgery procedures#2017-207

QUENTRIC Y (a), DAULL P (b), GROS E (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), GARRIGUE JS (b)
ARVO meeting 2017; Baltimore - USA. ARVO e-abstract No. 5297 - Poster B0250

(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

Binding to ocular albumin as a half-life extension. Principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies#2017-206

FUCHS H (a), IGNEY F (a)
J. Ocul. Pharmacol. Ther. 2017; DOI: 10.1089/jop.2016.0083 (collaboration)
(a) BOEHRINGER INGELHEIM PHARMA GmbH & Co. KG, Biberach an der Riss, Germany

Efficacy of a preservative-free cationic emulsion vehicle eye drop in a mouse model of dry eye#2016-223

QUENTRIC Y (a), DAULL P (b), FERAILLE L (a), ELENA PP (a), GARRIGUE JS (b)
ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 422. doi:
(a) IRIS PHARMA, La Gaude, France - (b) NOVAGALI Innovation Center, SANTEN SAS, Evry, France

Norbixin protects retinal pigmented epithelium cells and photoreceptors against A2E-mediated phototoxicity in vitro and in vivo#2016-205

FONTAINE V (a), MONTEIRO E (a), BRAZHNIKOVA E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)
PLOS ONE 11(12): e0167793. doi: 10.1371/journal.pone.0167793
(a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France

Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye#2016-204

DAULL P (a), FERAILLE L (b), BARABINO S (c), CIMBOLINI N (b), GRILLO-ANTONELLI S (b), MAURO V (b), GARRIGUE JS (a)
 Exp. Eye Res. 2016; Oct 21; 153:159-164
 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



Ocular tolerance in rabbits of intracameral administration of MYDRANE, a fixed combination of tropicamide, phenylephrine, and lidocaine for cataract surgery#2016-202

OLMIERE C (a), VIAUD K (b)
 EVER meeting 2016; Nice - France
 (a) LABORATOIRES THEA, Clermont-Ferrand, France - (b) IRIS PHARMA, Nice, France



SMA+ perivascular cells evaluation in VEGF induced blood-retinal barrier breakdown in rabbit model#2016-201

ELENA PP (a), MAURO V (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), VIAUD-QUENTRIC K (a), FERAILLE L (a)
 EVER meeting 2016; Nice - France
 (a) IRIS PHARMA, La Gaude, France



Pre-clinical in vivo (animal) testing of ocular formulations and drug delivery systems#2016-200

ELENA PP (a)
 Ocular Drug Delivery; Berlin - Germany. Oral communication
 (a) IRIS PHARMA, La Gaude, France



Comparative efficacy of cyclosporine A eye drop formulations in a mouse model of dry eye#2016-199

GARRIGUE JS (a), DAULL P (a), FERAILLE L (b), BARABINO S (c)
 ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57(12): 421. doi:
 (a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genoa, Italy



BIO201: a new drug candidate for the treatment of dry AMD#2016-198

FONTAINE V (a), BRAZHNKOVA E (a), MONTEIRO E (a), LESAGE L (a), BALDUCCI C (b), GUIBOUT L (b), FERAILLE L (c), ELENA PP (c), SAHEL JA (a), VEILLET S (b), LAFONT R (b)
 ARVO meeting 2016; Seattle - USA. Invest. Ophthalmol. Vis. Sci. 2016; 57: 1119. doi:
 (a) INSTITUT DE LA VISION, Paris, France - (b) BIOPHYTIS, Paris, France - (c) IRIS PHARMA, La Gaude, France



Long-term tolerance of preservative-free eye drops containing macrogol hydroxystearate as an excipient / Tolérance à long terme d'un collyre sans conservateur contenant comme excipient du macrogol hydroxystearate#2016-197

VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)
 J. Fr. Ophthalmol. 2016; Feb; 39(2): 156-63; doi : 10.1016/j.jfo.2015.09.011
 (a) IRIS PHARMA, Nice, France



Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping#2016-196

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)
 J. Ocul. Pharmacol. Ther. 2016; DOI: 10.1089/jop.2015.0054
 (a) SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



HL036337 ophthalmic solution: topical TNF blocker for dry eye disease#2015-216

Protein and AntiboPEGS meeting 2015; Boston, MA (collaboration)
 HanAll BioPharma Co., Ltd, Seoul, Korea



Cationic emulsion of cyclosporine for the management of ocular surface inflammation: a preclinical evaluation#2015-195

DAULL P (a), FERAILLE L (b), AMRANE M (a), ELENA PP (b), GARRIGUE JS (a)
 IOIS meeting 2015; San Francisco – USA
 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



Comparison of CKC- and BAK-cationic emulsions in a rat model of corneal wound healing#2015-194

DAULL P (a), FERAILLE L (b), ELENA PP (b), GARRIGUE JS (a)
 EVER meeting 2015; Nice – France. Poster T034
 (a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France



Evaluation of a cyclosporine A ophthalmic ointment in an experimental mouse model of dry eye#2015-193

CIMBOLINI N (a), ANTONELLI S (a), MAURO V (a), FERAILLE L (a), ELENA PP (a)
 EVER meeting 2015; Nice – France. Poster T031
 (a) IRIS PHARMA, La Gaude, France



Efficacy evaluation of a cationic emulsion of cyclosporine in a mouse model of dry eye

DAULL P (a), FERAILLE L (b), BARABINO S (c), GARRIGUE JS (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 4468 - Poster A0094

(a) NOVAGALI Innovation Center, SANTEN SAS, Evry, France - (b) IRIS PHARMA, La Gaude, France - (c) CLINICA OCULISTICA, Genova, Italy

#2015-192



Effects of the multi-kinase inhibitor regorafenib on ocular neovascularization

KLAR J (d), BOETTGER M (a,d), FREUNDLIEB J (c), KELDENICH J (c), ELENA PP (b), VON DEGENFELD G (d)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 243 - Poster C0118

(a) Clinical Sciences Experimental Medicine, BAYER PHARMA AG, Wuppertal, Germany - (b) IRIS PHARMA, Nice, France - (c) BAYER PHARMA AG, Wuppertal, Germany - (d) Ophthalmology, BAYER PHARMA AG, Wuppertal, Germany

#2015-191



Comparison of the effect of dexamethasone and prednisolone acetate in a rat model of glucocorticoid-induced ocular hypertension following topical delivery

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), BOUZIN M (a), FERAILLE L (a), VIAUD-QUENTRIC K (a), NICOLAS MF (b), LAURENT S (c), BLOT C (c)

ARVO meeting 2015; DENVER, CO - USA. ARVO e-abstract No. 2001 - Poster D0244

(a) IRIS PHARMA, Nice, France - (b) SANOFI R&D - LGCR, Vitry-sur-Seine, France (c) SANOFI R&D - Ophthalmology Unit, Paris, France

#2015-190



In vivo ocular tolerance of a new preservative-free eye drop formulation in rabbits

QUENTRIC Y (a), VIAUD K (a), LEFRANC-JULLIEN S (a), FERAILLE L (a), ELENA PP (a)

ARVO meeting 2015; Denver, CO - USA. ARVO e-abstract No. 802 - Poster D0264

(a) IRIS PHARMA, Nice, France

#2015-189



Systemic treatment with glutathione PEGylated liposomal methylprednisolone (2B3-201) improves therapeutic efficacy in a model of ocular inflammation

Invest. Ophthalmol. Vis. Sci. 2014; 55: 2859. doi: (collaboration)

TO-BBB TECHNOLOGIES BV, Leiden, Netherlands

#2014-224



The effect of preservatives and antiglaucoma treatments on the ocular surface of mice with dry eye

BARABINO S (a), ANTONELLI S (b), CIMBOLINI N (b), MAURO V (b), BOUZIN M (b)

Invest. Ophthalmol. Vis. Sci. 2014; 55:6499-6504 doi:10.1167/iovs.14-14548

(a) CLINICA OCULISTICA, GENOCA, ITALY - (b) IRIS PHARMA, Nice, France

#2014-188



Two simple animal models of intraocular pressure elevation for testing therapeutic drugs in glaucoma

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), ELENA PP (a)

EVER meeting 2014; Nice – France. Poster T017

(a) IRIS PHARMA, Nice, France

#2014-187



Regulatory issues related to preclinical animal research

ELENA PP (a)

ARVO meeting 2014; Orlando, FL - USA. Oral communication

(a) IRIS PHARMA, Nice, France

#2014-186



Plasma and ocular pharmacokinetic study comparing 3 µL micro-drop to typical 40 µL drop volume of timolol 0.5% in pigmented rabbits

VAN DER HEIDEN H (a,b), AMAR T (c), LICHTENAUEUR W (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 453 - Poster D0072

(a) MU-DROP, Apeldoorn, Netherlands - (b) ZAMB, Hospital Pharmacy, Tilburg, Netherlands - (c) IRIS PHARMA, Nice, France

#2014-185



Ocular pharmacokinetic study comparing ramipril and ramiprilat formulations administered orally or topically in pigmented rabbits

QUENTRIC Y (a), AMAR T (a), BARRE N (a), FERAILLE L (a), REKIK R (b)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 2360 - Poster B0036

IRIS PHARMA, Nice, France - (b) OPHTHALMOLOGY CLINIC, Tunis, Tunisia

#2014-184



Safety and tolerability of drugs within the suprachoroidal space in albino rabbits

PATEL S (a), VERHOEVEN R (a), BURKE B (a), CACCIAMANI F (b), VIAUD-QUENTRIC K (b), EDELHAUSER H (c,a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 4886 - Poster C0082

(a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France - (c) EMORY UNIV EYE CENTER, Atlanta, GA, USA

#2014-183



Biocompatibility of MedinGel biodegradable drug delivery system in the eye

SPIS M (a), FERAILLE L (b), ANTONELLI S (b), CIMBOLINI N (b), ELENA PP (b), GAUDRIAULT G (a), PETIT A (a)

ARVO meeting 2014; Orlando, FL - USA. ARVO e-abstract No. 5273 - Poster C0069

(a) MEDINCELL, Jacou, France - (b) IRIS PHARMA, Nice, France

#2014-182



Dry eye: two experimental rodent models for drug development

CIMBOLINI N (a), ANTONELLI S (a), BARABINO S (b), FERAILLE L (a), MARGARON P (a), ELENA PP (a)
 TFOS meeting 2013; Taormina - Sicily - Italy
 (a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genova, Italy

**Effects of cyclosporine in an experimental rat model of dry eye**

CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)
 EVER meeting 2013; Nice – France. Poster S008
 (a) IRIS PHARMA, Nice, France

**Impact of the routes of administration on the effects of cyclosporine in an experimental rat model of dry eye**

CIMBOLINI N (a), GRILLO-ANTONELLI S (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)
 ISOPT meeting 2013; Paris – France
 (a) IRIS PHARMA, Nice, France

**CLS1001 suprachoroidal injectable suspension of triamcinolone acetonide is well tolerated in the albino rabbit**

VERHOEVEN R (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), PATEL S (a)
 American College of toxicology 2013 San Antonio, Texas - USA. Poster P505
 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

**Suprachoroidal microinjection of triamcinolone acetonide is well tolerated in the albino rabbit**

VERHOEVEN R (a), PATEL S (a), VIAUD-QUENTRIC K (b), CACCIAMANI F (b), AMAR T (b), YERXA B (a)
 ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 119 - Poster C0124
 (a) CLEARSIDE BIOMEDICAL, Alpharetta, GA, USA - (b) IRIS PHARMA, Nice, France

**Comparison of two rodent models of dry eye induced by scopolamine**

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), FERAILLE L (a), BARABINO S (b), MARGARON P (a)
 ARVO meeting 2013; Seattle, WA - USA. ARVO e-abstract No. 6002 - Poster A0065
 (a) IRIS PHARMA, Nice, France - (b) CLINICA OCULISTICA, Genova, Italy

**Assessment of a new device for conjunctival impression**

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c)
 MCLOSA meeting 2012; London - England
 (a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology, Quinze-Vingts Hospital, Paris, France

**Protection of blue light induced retinal degeneration by the free radical scavenger phenyl-N-tert-butylnitronate and a serotonin receptor 5-HT1a agonist in rats**

GRILLO-ANTONELLI S (a), CIMBOLINI N (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a), ELENA PP (a)
 EVER meeting 2012; Nice - France. Poster S063
 (a) IRIS PHARMA, Nice, France

**Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping**

DAULL P (a), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c), GARRIGUE JS (a)
 EVER meeting 2012; Nice - France. Poster T036
 (a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

**Ocular surface effects of antiglaucoma combination therapies in a rat model of corneal scraping**

DAULL P (a), GARRIGUE JS (a), FERAILLE L (b), BAUDOUIN C (c), ELENA PP (b)
 EVER meeting 2012; Nice - France. Poster T037
 (a) NOVAGALI PHARMA SA, Evry, France - (b) IRIS PHARMA, Nice, France - (c) INSTITUT DE LA VISION, Paris, France

**Multiple topical administrations of Ramipril enhance retinal ganglion cell survival after transient retinal ischemia-reperfusion in rats**

ELENA PP (a), VIAUD-QUENTRIC K (a), CHARFEDDINE R (b), REKIK R (c)
 EVER meeting 2012; Nice - France. Poster F029
 (a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

**Augmentation of the ocular penetration of dexamethasone with β -blocker and α -agonist co-administration**

ELENA PP (a), SENSEBY F (a), BERMON F (a), CHARFEDDINE R (b), REKIK R (c)
 EVER meeting 2012; Nice - France. Poster F107
 (a) IRIS PHARMA, Nice, France - (b) UNIMED, Sousse, Tunisie - (c) Ophthalmology Clinic, Tunis, Tunisia

**Anti-inflammatory effects of glucocorticoids on endotoxin-induced uveitis in rats: effects of the mode of administration**

ELENA PP (a), CIMBOLINI N (a), ANTONELLI S (a), DUBOS H (a), FERAILLE L (a), MARGARON P (a)
 ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6285 - Poster D 1145
 (a) IRIS PHARMA, Nice, France



Assessment of intra-ocular pressure lowering effect of novel gel formulations of Latanoprost and Timolol in nonhuman primates following topical delivery#2012-167

GOODY RJ (a), WHITTAKER S (a), HENRY S (a), BROOKES R (a), STRUHARIK M (a), BERMON F (b), MARGARON P (b), POLZER H (c), LAWRENCE MS (a)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1968 - Poster D 812
(a) RXGen, Hamden, CT - (b) IRIS PHARMA, Nice, France - (c) MEDPROJECT PHARMA, Bayern, Germany



Assessment of a new device for conjunctival impression#2012-166

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b), BAUDOUIN C (c)
ARVO meeting 2012; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1868 - Poster A 331
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France - (c) Ophthalmology Quinze-Vingts Hospital, Paris, France



Assessment of a new device for conjunctival impression#2011-165

ROY P (a), CIMBOLINI N (b), ANTONELLI S (b), FERAILLE L (b), ELENA PP (b)
ISOPT meeting 2011; Vienna, Austria (oral presentation)
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France



Evaluation of membrane material for impression cytology#2011-161

ROY P (a), CIMBOLINI N (b), FERAILLE L (b), KECHAD M (b), ELENA PP (b)
ARVO meeting 2011; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1937 - Poster D 918
(a) OPIA Technologies, Paris, France - (b) IRIS PHARMA, Nice, France



Ocular distribution and spectrum of activity of a fully human anti-herpes simplex virus IgG Fab fragment, following topical application#2010-160

BERDUGO-POLAK M (a,b), LARSEN IV (c), ABADIE C (d), KOWALCZUK L (a,b), TOUCHARD E (a,b), NELSON JD (e), ELENA PP (f), BRANDT CR (c), BEHAR-COHEN F (a,b,g), COMBETTE JM (d)
ARVO meeting 2010; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1991/ D1028
(a) INSERM UMRS 872, Paris, France - (b) Pierre et Marie Curie University, Paris, France - (c) University of Wisconsin School of Medicine and Public Health, Madison, WI - (d) ribOvax Biotechnologies, Petit-Lancy, Switzerland - (e) Calmune Corporation, San Diego, CA - (f) IRIS PHARMA, La Gaude, France - (g) Hotel-Dieu University Hospital, Paris, France



Designing dendrimers for ocular delivery#2010-157

SPATARO G (a,b), MALECAZE F (c), TURRIN CO (a,b), SOLER V (c), DUHAYON C(a,b), ELENA PP (d), MAJORAL JP (a,b), CAMINADE AM (a,b)
Eur. J. Med. Chem. 2010; 45: 326-334
(a) CNRS, Laboratoire de Chimie de Coordination, Toulouse, France - (b) Université de Toulouse, Toulouse, France - (c) Hôpital Purpan, Toulouse, France - (d) IRIS PHARMA, Nice, France



Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation#2009-156

AKPEK EK (a), VITITITOW J (b), VERHOEVEN RS (b), BRUBAKER K (b), AMAR T (c), POWELL KD (d), BOYER JL (b), CREAN C (b)
J. Ocul. Pharmacol. Ther. 2009; 25: 433-439
(a) THE WILMER EYE INSTITUTE, Johns Hopkins Hospital, Baltimore, USA - (b) INSPIRE Pharmaceuticals, Durham, USA - (c) IRIS PHARMA, Nice, France - (d) ENTHALPY ANALYTICAL, Durham, USA



Corneal effect of topical diclofenac co-administration with aminoside and steroid in rabbits#2009-154

CAILLAUD T (a), VIAUD K (a), ELENA PP (a)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 1957
(a) IRIS PHARMA, Nice, France



Snapshot test for investigating gels of anti-glaucoma compounds as topical formulations#2009-153

ELENA PP (a), POLLIN C (a), BERMON F (a), AMAR T (a), CAILLAUD T (a), POLZER H (b)
ARVO meeting 2009; Fort Lauderdale, FL - USA. ARVO e-abstract No. 6002
(a) IRIS PHARMA, Nice, France - (b) MEDPROJECT PHARMA, Bayern, Germany



Ocular pharmacokinetic study following single and multiple azithromycin administrations in pigmented rabbits#2008-152

AMAR T (a), CAILLAUD T (a), ELENA PP (a)
Curr Eye Res. 2008; 33: 149-158
(a) IRIS PHARMA, Nice, France



Immunohistochemistry and in situ zymography to assess matrix metalloproteinases expression and activation by latanoprost in rat uveoscleral pathway#2008-149

ELENA PP (a), FRETON A (a), SPADAFORA A (a), GRILLO-ANTONELLI S (a), CIMBOLINI N (a), FERAILLE L (a), LAZDUNSKI M (b)
ARVO meeting 2008; Fort Lauderdale, FL - USA. ARVO e-abstract No. 2616
(a) IRIS PHARMA, Nice, France - (b) IPMC-UMR 6097, Valbonne, France



Comparaison in vivo de médicaments anti-allergiques avec microscope confocal afin d'évaluer la réponse tardive à l'anaphylaxie induit chez le cobaye#2007-242



FERAILLE L (a)
AOP 2007 - S85 ; Paris - France. Oral communication in French
(a) IRIS PHARMA, Nice, France

Netildex versus Tobradex®: ocular pharmacokinetic/pharmacodynamic after a single dose and after one-day treatment in pigmented rabbits#2007-226



CIVIALE C (a), BLANCO A (a), SUDANO-ROCCARO A (a), AMAR T (b) MAZZONE M (a)
Invest. Ophthalmol. Vis. Sci. 2007; 48(13):4272. doi:
(a) SIFI SPA, Lavinaio-Aci San Antonio, Italy - (b) IRIS PHARMA, Nice, France

Ether-lipid-deficient-mice display pigmentary glaucoma features as well as abnormal retinal vasculature#2007-225

ACAR N (a), SICARD P (b), SCHNEBELEN C (a), CIMBOLINI N (c), IVINGS L (a), GRILLO-ANTONELLI S (c), ROCHELLE L (b), CREUZOT-GARCHER CP (a,d), BRETILLON L (a), JUST WW (e)
ARVO meeting 2007; Fort Lauderdale, FL - USA. Investigative Ophthalmology & Visual Science May 2007, Vol.48, 2978. doi:
(a) INRA, Dijon, France - (b) Faculties of Medicine and Pharmacy, Dijon, France - (c) IRIS PHARMA, Nice, France - (d) University Hospital, Dijon, France - (e) Biochemie Zentrum Heidelberg (BZH), Heidelberg, Germany

Cationic oil-in-water emulsion as an improved cyclosporine ocular vehicle for vernal keratoconjunctivitis sicca (VKC)#2007-148



LAMBERT G (a), RABINOVICH-GUILATT L (a)
ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO poster No. 2301/B999 (collaboration)
(a) NOVAGALI PHARMA SA, Evry, France

Ocular tolerability of iontophoresis#2007-147

ROY P (a), ELENA PP (b), VIAUD K (b), CAILLAUD T (b), CALIAS P
ARVO meeting 2007; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5800
(a) EYEGATE Pharmaceuticals, Waltham, USA - (b) IRIS PHARMA, Nice, France

New evaluation techniques in ocular surface diseases: comparison of antiallergic drugs using in vivo confocal microscopy for assessing late response of induced ocular anaphylaxis in the guinea pig#2007-146



FERAILLE L (a)
Oral presentation. EVER meeting 2007; Portoroz, Slovenia
(a) IRIS PHARMA, Nice, France

Update on drug delivery systems used in the anterior part of the eye: review of the new drug delivery systems for the anterior chamber#2007-145



ELENA PP (a)
Oral presentation. ESCRS meeting 2007; Stockholm, Sweden
(a) IRIS PHARMA, Nice, France

In vivo characterization of the anti-inflammatory effect of a multikinase inhibitor targeting angiogenesis and inflammation#2007-141



JENSEN L (a), HJARNAA P (a), FENSHOLDT J (a), ELENA PP (b), ABELL K (a), PETERSEN TK (a)
8th World Congress on Inflammation 2007; Copenhagen, Denmark. Inflamm Res. 2007; 56(suppl.3): S443, abstract P07.21
(a) LEO PHARMA, Ballerup, Denmark - (b) IRIS PHARMA, Nice, France

The role of the CROs in the ophthalmological drug development in Europe#2006-140

ELENA PP (a)
Oral presentation. ISOPT meeting 2006; Berlin, Germany
(a) IRIS PHARMA, Nice, France

Pharmacokinetics of clonidine after a single application of transscleral iontophoresis in rabbits#2006-131



CAILLAUD T (a), ROY P (b), VIAUD K (a), ELENA PP (a)
ARVO meeting 2006; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2006; 47: ARVO e-abstract No. 5109
(a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Influence of solution composition and electrode design on transscleral iontophoresis delivery of dexamethasone disodium phosphate#2006-130



ROY P (a), VIAUD K (b), CAILLAUD T (b), ELENA PP (b)
ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5110
(a) EYEGATE, Paris, France - (b) IRIS PHARMA, Nice, France

Evaluation of ocular tolerability of repetitive corneal-scleral iontophoresis in pigmented rabbits

#2006-129

ELENA PP (a), **ROY P** (b), **VIAUD K** (a), **CAILLAUD T** (a)
 ARVO meeting 2006; Fort Lauderdale, FL - USA. ARVO e-abstract No. 5094
 (a) IRIS PHARMA, Nice, France - (b) EYEGATE, Paris, France

Effects of dexamethasone in a rat model of choroidal neovascularization

#2006-128

FERAILLE L (a), **GRILLO-ANTONELLI S** (a), **CIMBOLINI N** (a), **CAILLAUD T** (a), **ELENA PP** (a)
 Ocular Anti-Angiogenesis meeting 2006; London - United Kingdom
 (a) IRIS PHARMA, Nice, France

Variation of krüppel-like factors levels in mouse corneal model of angiogenesis

#2005-127

CHIAMBARETTA F, **DE GRAEVE F**, **FERAILLE L**, **NEZZAR H**, **MARCEAU G**, **DASTUGNE B**, **RIGAL D**, **ELENA PP**, **SAPIN V**
 ARVO meeting 2005; Fort Lauderdale, FL. Invest. Ophthalmol. Vis. Sci. 2005; 46: ARVO e-abstract No. 2609

Variation of krüppel-like factors ARNm levels in a mouse corneal model of angiogenesis

#2005-123

CHIAMBARETTA F, **NEZZAR H**, **FERAILLE L**, **DE GRAEVE F**, **MARCEAU G**, **ELENA PP**, **RIGAL D**, **DASTUGUE B**, **SAPIN V**
 SFO meeting 2005; Paris – France. Abstract No. 380

PKC412 content in retina, choroid and plasma of pup mice with retinal neovascularization induced by hyperoxic stimuli

#2004-116

ELENA PP (a), **AMAR T** (a), **CAILLAUD T**(a), **WONG M** (b), **BIZEC JC** (C)
 ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4053
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS PHARMA, EAST HANOVER, USA - (C) NOVARTIS PHARMA AG, Basel, Switzerland

PKC412 reduces retinal neovascularization induced by hypoxic stimuli in pup mice

#2004-115

CAILLAUD T (a), **AMAR T** (a), **OTTLECZ A** (b), **WONG M** (c), **LAMBOU GN** (b), **ELENA PP** (a)
 ARVO meeting 2004; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2004; 45: ARVO e-abstract No. 4062
 (a) IRIS PHARMA, Nice, France - (b) NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland - (c) NOVARTIS PHARMA, East Hanover, USA

In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression

#2003-114

CHABRY J, **RATSIMANOHATRA C**, **SOPPNE I**, **ELENA PP**, **VINCENT JP**, **PILLOT T**
 J Neurosci. 2003; Jan 15; 23(2): 462-9

Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit

#2002-111

TESSIE G, **SEBASTIAN C**, **ELENA PP**, **DRIOT JY**, **TRINQUAND C**
 J. Ocul. Pharmacol. Ther. 2002; 18: 65-73

Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits

#2001-113

YERXA BR, **DOUGLASS JG**, **ELENA PP**, **CAILLAUD T**, **AMAR T**, **REDICK CC**, **PETERSON WM**
 Adv. Exp. Med. Biol. 2002; 506: 261-265

Topical ocular instillation of nitric oxide synthase inhibitors and intraocular pressure in rabbits

#2001-110

FLEISCHHAUER JC, **LIU R**, **ELENA PP**, **FLAMMER J**, **HAEFLIGER IO**
 Klin. Monatsbl. Augenheilkd. 2001; 218: 351-353

Ocular distribution of CAT-152 after a single subconjunctival injection in a pigmented rabbit model of glaucoma filtration surgery

#2001-108

ELENA PP, **MCFARLANE S**, **GLOVER DR**, **AMAR T**, **CAILLAUD T**
 ARVO meeting 2001; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 2001; 42: S544, abstract No. 2915

Effect of CO₂ pneumoperitoneum on early cellular markers of retinal ischemia in rabbits with α-chymotrypsin-induced glaucoma

#2000-234

LENTSCHENE C (a) , **FREDJ-REYGROBELLET D** (b), **BOUAZIZ H** (c), **MAZOIT JX** (d), **NIESSEN F** (a), **BENHAMOU D** (a)
 Surg. Endosc. 2000; 14: 1057–1961 DOI: 10.1007/s004640000257 (collaboration)
 (a) Hôpital Antoine Béclère, Clamart, France - (b) Faculté de Médecine Nice, France - (c) Hôpital Central, Nancy, France - (d) Hôpital de Bicêtre, le Kremlin Bicêtre Cedex, France

A new long acting ophthalmic formulation of carteolol containing alginic acid

#2000-106

SECHOY O, **TESSIE G**, **SEBASTIAN C**, **MAURIN F**, **DRIOT JY**, **TRINQUANT C**
 Int. J. Pharm. 2000; 207: 109-116. (collaboration)

Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension#2000-104

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND J, LE FUR G
J. Ocul. Pharmacol. Ther. 2000; 16: 203-216



Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits#2000-103

PISELLA PJ (a,b), FILLAGIER K (d), **ELENA PP** (e), DEBBASCH C (b,c), BAUDOUIN C (a)
Ophthalmic Res. 2000; 32: 3-8

(a) Department of Ophthalmology, Ambroise Paré Hospital, APHP, Paris, France - (b) Toxicology Laboratory, University of Paris-V René Descartes, Paris, France - (c) Department of Cellular Pharmacotoxicology, XV-XX Hospital, Paris, France - (d) Department of Ophthalmology, University of Nice, France - (e) IRIS PHARMA, Nice, France



Localisation of Venoruton in rat blood vessel after single oral administration#2000-102

SALLIN D, **ELENA PP**, ZIJLSTRA J
14th World Congress of the 'Union Internationale de Phlebologie' Roma - Italy 2000

Evaluation of a novel carteolol eye-drops with alginic acid as long action promoter#2000-101

TISSIE G, SEBASTIAN C, MAURIN F, SECHOY O, DRIOT JY, **ELENA PP**, TRINQUAND C
EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 29, abstract No. 214

Alginic acid effect on ocular distribution of carteolol after a single instillation in pigmented rabbits#2000-100

SEBASTIAN C, TISSIE G, DRIOT JY, **ELENA PP**, TRINQUAND C
EVER meeting 2000; Palma de Mallorca, Spain. Ophthalmic Res. 2000; 32(S2): 28, abstract No. 215

Potency and duration of action of synthetic P2Y2-receptor agonists on schirmer scores in rabbits#2000-99

YERXA BR, DOUGLASS JG, **ELENA PP**, CAILLAUD T, AMAR T, PETERSON WM
(3rd International Conference on the Lacrimal Gland, Tear Film and Dry Eye Syndromes Maui, HI - USA) Cornea 2000; 19: S138

Ethics committee recommendations for laboratory animals in private research in France#2000-98

B. VERSCHUERE B, AUTISSIER C, DEGRYSE AD, GALLIX P, GOTTI B, LAURENT J, LEINOT M, PEYCLIT I
Laboratory Animals 2000; 34: 236-243. (collaboration)

Learning deficits in first generation OF1 mice deficient in (n-3) polyunsaturated fatty acids do not result from visual alteration#1999-249

CARRIE I (a), CLEMENT M (a), DE JAVEL D (a), FRANCES H (b), BOURE JM (a) (collaboration)
Neurosci. Lett. 1999; 266: 69-72 doi: 10.1016/S0304-3940(99)00265-7
(a) INSERM U26, Paris, France - (b) Institut de recherche biologique Yves Ponroy, Les Clayes Sous Bois, France



Benefits of a vasopressin V2 receptor antagonist, SR 121463, in the treatment of ocular hypertension in the rabbit#1999-97

SERRADEIL-LE GAL C, LACHERETZ F, BARBIER A, **ELENA PP**, PASCAL M, MAFFRAND JP, LE FUR G
World Congress on Neurohypophyseal Hormones. 1999; Edinburgh – UK

INS365, a P2Y2 receptor agonist, increases schirmer scores in albino rabbits#1999-96

YERXA BR, **ELENA PP**, CAILLAUD T, AMAR T, EVANS R
ARVO meeting 1999; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1999; 40: S540, abstract No. 2848



Inflammation measurement and immunocharacterization of cell proliferation in an experimental model of proliferative vitreoretinopathy#1998-95

BAUDOUIN C, KHOSRAVI E, PISELLA PJ, ETTACHE M, **ELENA PP**
Ophthalmic Res. 1998; 30: 340-350



The effect of pneumoperitoneum on intraocular pressure in rabbits with α -chymotrypsin-induced glaucoma#1998-94

LENTSCENER C, LEVEQUE JP, MAZOIT JX, BENHAMOU D
Anesth. Analg. 1998; 86: 1283-1288. (collaboration)

Activity of SR121463, a selective non-peptide vasopressine V2 receptor antagonist, in a rabbit model of glaucoma#1998-93

LACHERETZ F, BARBIER A, SERRADEIL-LE GAL C, **ELENA PP**, MAFFRAND JP, LE FUR G
(ISER 1998 Abstract No. 795; Paris - France) Exp. Eye Res. 1998; 67: S239

Protective effect of nicardipine, a calcium channel blocker on electroretinogram and retinal cytoskeletal damages after ischemia-reperfusion on the rat#1998-92

FREDJ-REYGROBELLET D, **CAILLAUD T, ELENA PP**

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S993, abstract No. 4591

Comparison of efficacy between ketotifen and olopatadine eyedrops in allergic conjunctivitis#1998-91

ELENA PP, AMAR T, FETZ A, SCHOCH C

ARVO meeting 1998; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1998; 39: S549, abstract No. 2531

Ocular distribution of lomefloxacin 0.3 % after a single instillation in the infected eye of pigmented rabbits#1997-90

ELENA PP, JAUCH A

J. Ocul. Pharmacol. Ther. 1997; 13: 551-558



Intraocular pressure effects of topical rilmenidine in ocular hypertensive animals and in healthy volunteers and glaucoma subjects#1997-89

NORDMANN JP, **ELENA PP, VILAIN C**

ISECOPP meeting 1997 Munich – Germany, p. 12

Analyse de l'inflammation et de la prolifération cellulaire intra-oculaires dans un modèle expérimental de prolifération vitréorétinienne#1997-87

PISELLA PJ, BECQUET F, **ELENA PP, BAUDOUIN C**

Ophthalmologie (France) 1997; 11: 369-371

Effects of different formulations of mitoxantrone (solutions, nanospheres, liposomes) on glaucoma surgery in rabbits#1997-86

TILLEUL P, DENIS P, MAIGNEN F, **ELENA PP, NORDMANN JP, LEVERGE R, ROSTENE W**

Ophthalmic Res. 1997; 29: 218-226



Retinal damage and protection after ischemic injury in the rat: a reappraisal#1997-85

ELENA PP, CAILLAUD T, AMAR T, HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S888, abstract No. 4151

Ocular distribution of Rescula® Eye-Drops in the pigmented rabbit after a single topical administration#1997-84

CAILLAUD T, AMAR T, HARITON C, ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S815, abstract No. 3796



Rilmenidine: effect on intraocular pressure in alpha-chymotrypsin rabbits#1997-83

AMAR T, NORDMANN JP, CASTAGNE I, VILAIN C, ELENA PP

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S814, abstract No. 3790

Protection induced by isopropyl unoprostone treatment after retinal ischemic injury in the rat#1997-76

MOREL-MANDRINO P, CAILLAUD T, ELENA PP, HARITON C

ARVO meeting 1997; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1997; 38: S103, abstract No. 502

Inflammation measurement and immunohistocharacterization of cell proliferation in experimental PVR#1996-81

BAUDOUIN C, PISELLA PJ, KHOSRAVI E, ETTAICHE M, ELENA PP

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S391, abstract No. 1808

Antiproliferative activity of a liposomal delivery system of mitoxantrone on rabbit subconjunctival fibroblasts in an ex-vivo model#1996-80

MAIGNEN F, TILLEUL P, BILLARDON C, XU-VAN OPSTAL WY, PELAPRAT D, **ELENA PP, DENIS P, ROSTENE W**

J. Ocul. Pharmacol. Ther. 1996; 12: 289-298

The renin-angiotensin system in the rabbit eye#1996-79

RAMIREZ M, DAVIDSON EA, LUTTENAUER L, **ELENA PP, CUMIN F, MATHIS GA, DE GASPARO M**

J. Ocul. Pharmacol. Ther. 1996; 12: 299-312



Histological and cytological retinal changes after pressure-induced ischemia in rat eye#1996-78

FREDJ-REYGROBELLET D, **TABIASCO J, BALAS D, DENIS P, ELENA PP**

(JERMOV 1996 Abstract No. 399; Montpellier - France) Vision Res. 1996; 36: S220

Pharmacokinetics of 0.1 % azelastine eyedrops, a histamine-H1-antagonist, with or without an induced allergic conjunctivitis#1996-77

ELENA PP, KHOSRAVI E, BORBE H, HERBST M, PETER G

ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S1027, abstract No. 4719

Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes#1996-74

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, LUYCKX J
ARVO meeting 1996; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1996; 37: S81, abstract No. 383

Distribution of Salicylate in Pigmented Rabbit Ocular Tissues After Application of a Prodrug, Sodium Monomethyl Trisilanol Orthohydroxybenzoate: In Vivo and Ex Vivo Studies#1995-248

CHANALET L, ETTAICHE M, BAUDOUIN C, LAPALUS P (collaboration)
J. Ocul. Pharmacol. Ther. 1995; 11:1, 83-94 doi: 10.1089/jop.1995.11.83



Allergic conjunctivitis and uveitis models: reappraisal with some marketed drugs#1995-73

KHOSRAVI E, ELENA PP, HARITON C
Inflamm. Res. 1995; 44: 47-54



Intraocular pressure effects of topical renin inhibitor CGP 38560 in normal and ocular hypertensive animals and in healthy volunteers and glaucoma subjects#1995-72

NORDMANN JP, PERCICOT CL, ELENA PP, MATHIS GA
ISECOPP meeting 1995; Geneva – Switzerland, p. 35



Lomefloxacin distribution after a single instillation in the infected eye of pigmented rabbits#1995-69

KHOSRAVI E, ELENA PP, JAUCH A
ISECOPP meeting 1995 Geneva - Switzerland, p. 67



Non-invasive measurement of ocular temperature by using infrared thermographic analysis in immune and non-immune allergy models#1995-68

ELENA PP, KHOSRAVI E, HARITON C
ISECOPP meeting 1995; Geneva - Switzerland, p. 60



The renin angiotensin system in the rabbit eye#1995-67

RAMIREZ M, DAVIDSON EA, ELENA PP, MATHIS GA, DE GASPARO M
ISECOPP meeting 1995; Geneva - Switzerland, p. 25

Lack of cytotoxic effect of ganciclovir and acyclovir on rabbit corneal epithelial cells in vitro#1995-66

KHOSRAVI E, ELENA PP, GOLDSCHMIDT P, BAUDOUIN C, LUYCKX J
JERMOV meeting 1995; Montpellier - France. Vision Res. 1995; 35: S173, abstract No. P125



Dimethindene maleate in allergic conjunctivitis: a new indication for an old drug#1995-65

ELENA PP, KHOSRAVI E, HARITON C
ARVO meeting 1995; Fort Lauderdale, FL - USA. Invest. Ophthalmol. Vis. Sci. 1995; 36: S1014, abstract No. 4699



Correlation between anterior chamber inflammation and proliferative vitreoretinopathy in the rabbit#1994-64

KHOSRAVI E, BAUDOUIN C, ELENA PP
JERMOV meeting 1994; Montpellier - France, p 240, abstract No. P192



Central nervous system control of intraocular pressure#1994-63

DENIS P, NORDMANN JP, ELENA PP, SARAUX H, and LAPALUS P
Fundam. Clin. Pharmacol. (France) 1994; 8: 230-237



Ocular distribution of nicergoline after intravenous administration in rats#1994-62

ELENA PP, BERTHOLOM N, KHOSRAVI E
JERMOV meeting 1994; Montpellier - France, p 173, abstract No. P12



Topical sodium sucrose octasulphate reduces corneal lesions in a keratoconjunctivitis sicca model in the rat#1994-61

CHIBRET H, ELENA PP, KHOSRAVI E, FREDJ-REYGROBELLET D
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1693, abstract No. 2039



Distribution of ganciclovir in the anterior uvea after topical application of 0.15 % ganciclovir gel to intact and HSV-infected eyes of rabbits#1994-60

ELENA PP, GOLDSCHMIDT P, CHAST F, SAUVAGEON H, LUYCKX J, KHOSRAVI E
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35: 1682, abstract No. 1984



Angiotensin-II antagonists reduce intraocular pressure by a combined effect on aqueous humor synthesis and outflow#1994-58

MATHIS GA, PERCICOT C, MERMOUD A, ELENA PP
ARVO meeting 1994; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1994; 35; 1483, abstract No. 1060



Physiological roles of dopamine and neuropeptides in the retina

....#1993-57

DENIS P, NORDMANN JP, **ELENA PP**, DUSSAILLANT M, SARAUX H, LAPALUS P
Fundam. Clin. Pharmacol. (France) 1993; 7: 293-304

Bioequivalence between timolol maleate formulated in ophthalmic solution (Timoptol®) and in a novel gel vehicle (T-Gel)

....#1993-56

ELENA PP, POLZER H, **KHOSRAVI E**
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1490, abstract No. 3902

Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium

....#1993-55

CHIBRET H, **ELENA PP**, **KHOSRAVI E**
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 1050, abstract No. 1712

Mifepristone (RU 486): in vitro binding to glucocorticoid receptors in iris-ciliary body and in vivo effects on intraocular pressure in rabbits

....#1993-54

DENIS P, **ELENA PP**, NORDMANN JP, SARIEAU A, SARAUX H, ROSTENE W
ARVO meeting 1993; Sarasota, FL - USA. Invest. Ophthalmol. Vis. Sci. 1993; 34: 925, abstract No. 1115

Piribédil : affinité pour les récepteurs dopaminergiques rétiniens et profil pharmacocinétique oculaire

....#1993-53

LAPALUS P, DENIS P, DRICI M, FREDJ-REYGROBELLET D, **ELENA PP**
J. Neur. 1993; 240 (Suppl 1): S17-S21

Retinal dopaminergic receptor affinity and ocular pharmacokinetic profile of piribedil

....#1992-52

LAPALUS P, DENIS P, DRICI M, FREDJ-REYGROBELLET D, **ELENA PP**
J. Neurol. 1992; 239 (Suppl 1): S17-S21

Ocular pharmacokinetics of trimetazidine in the pigmented rat after a single oral administration

....#1992-51

ELENA PP, **KHOSRAVI E**, LAPALUS P, JOULIN Y, HARPEY C
ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S55, abstract No. 184

Effect of diclofenac sodium and diclofenac sodium SDU eyedrops on prostaglandin concentrations in aqueous humor of rabbits after extracapsular surgery

....#1992-50

ELENA PP, ULRICH E, TSCHÄLÄR Y, LAPALUS P, **ETTAICHE M**, **KHOSRAVI E**
ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 183

Ocular pharmacokinetics of two preservatives, benzalkonium chloride or benzoxonium chloride, after instillation in the pigmented rabbit

....#1992-49

ELENA PP, **KHOSRAVI E**, LAPALUS P, ULRICH E
ISER meeting 1992; Stresa - Italy. Exp. Eye Res. 1992; 55: S54, abstract No. 182

Preclinical pharmacokinetics of the 14C-labelled aldose reductase inhibitor methosorbinil (E-0722)

....#1992-48

ELENA PP, KUNZ PA, LAPALUS P
SOE meeting 1992; Brussels - Belgium, p. 188, abstract No. 737

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

....#1991-47

DENIS P, **ELENA PP**, NORDMANN JP, DUSSAILLANT M, LAPALUS P, SARAUX H, ROSTENE W
"Physiologie, Pathologie et Génétique Oculaire." CHRISTEN Y AND DROIX-LEFAIX MT ed. (Springer Verlag, Paris, 1991), 105-113

Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme

....#1991-46

LAPALUS P, **ELENA PP**, NORDMANN JP, LAROCHE L, SARAUX H, LAPALUS P
Ophthalmologie (France) 1991; 5: 53-56

Localization and characterization of substance P binding sites in rat and rabbit eyes

....#1991-45

DENIS P, FARDIN V, NORDMANN JP, **ELENA PP**, LAROCHE L, SARAUX H, ROSTENE W
Invest. Ophthalmol. Vis. Sci. 1991; 32: 1894-1902

Autoradiographic characterization and localization of vasoactive intestinal peptide binding sites in albino rat and rabbit eyes

....#1991-44

DENIS P, DUSSAILLANT M, NORDMANN JP, **ELENA PP**, SARAUX H, ROSTENE W
Exp. Eye Res. 1991; 52: 357-366

Autoradiographic localization of β -adrenergic binding sites in human retinal blood vessels

....#1991-43

DENIS P, ELENA PP, LAPALUS P

Chibret Int. J. 1991; 7: 14-19

Distribution rétinienne des sites récepteurs dopaminergiques rétiniens chez l'homme. Hypothèses fonctionnelles sur le rôle de la dopamine dans la vision

....#1991-42

DENIS P, NORDMANN JP, ELENA PP, LAPALUS P

(Dopamine, Fonctions Cérébrales et Neurosensorielles; Budapest - Hungary 1991) Euthérapie

Autoradiographic localization of D1 and D2 dopamine binding sites in the human retina

....#1990-41

DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P

Neurosci. Lett. 1990; 116: 81-86

 β -adrenergic binding sites in the human eye: an autoradiographic study

....#1990-40

ELENA PP, DENIS P, KOSINA-BOIX M, SARAUX H, LAPALUS P

J. Ocul. Pharmacol. 1990; 6: 143-149

Localisation et caractérisation autoradiographiques de sites de liaison oculaires du VIP (Vasoactive Intestinal Peptide) chez le rat et le lapin albinos

....#1990-39

DENIS P, DUSSAILLANT M, ELENA PP, NORDMANN JP, ROSTENE W, LAROCHE L

Ophtalmologie (France) 1990; 4: 30-32

Cytotoxicity studies in ophthalmology

....#1990-38

LAPALUS P, ETTAICHE M, FREDJ-REYGROBELLET D, JAMBOU D, ELENA PP

Lens Eye Toxic Res. 1990; 7: 231-242

Ocular pharmacokinetics of ganciclovir gel after a single administration

....#1990-37

LAPALUS P, ETTAICHE M, LUYCKX J, ELENA PP

AER meeting 1990; Bad Honnef - Germany, p 58, abstract No. 94

Hymecol pharmacokinetics after a single intracameral injection in phakic and aphakic eyes of pigmented rabbits

....#1990-36

ELENA PP, LAPALUS P, FREDJ-REYGROBELLET D, ETTAICHE M, ULRICH E

AER meeting 1990; Bad Honnef - Germany, p 25, abstract No. 6

Specific receptors to vasculotropin in the eye

....#1990-35

MOUKADIRI H, DENIS P, ELENA PP, ROSTENE W, PLOUET J

AER meeting 1990; Bad Honnef - Germany, p 24, abstract No. 4

Localization and characterization of receptors in human and animal eyes by "in vitro" autoradiography

....#1990-34

ELENA PP, DENIS P, FREDJ-REYGROBELLET D, ROSTENE W, LAPALUS P

ISER meeting 1990; Helsinki - Finland, p 228, abstract No. 803

Autoradiographic localisation of insulin binding sites in the human eye

....#1990-33

DENIS P, ELENA PP, LE MARCHAND-BRUSTEL Y, NORDMANN JP, LAPALUS P, SARAUX H

ISER meeting 1990; Helsinki - Finland, p 114, abstract No. 384

Retinal dopaminergic receptors and distribution of piribedil

....#1990-32

LAPALUS P, ELENA PP, FREDJ-REYGROBELLET D, DENIS P

ENS meeting 1990; Brighton – UK

Localisation et caractérisation radioautographiques des récepteurs β -adrénergiques oculaires dans les structures non pigmentées chez l'homme

....#1990-31

DENIS P, ELENA PP, NORDMANN JP, SARAUX H, LAPALUS P

SFO meeting 1990; Paris – France

La radioautographie en ophtalmologie : méthodologie et applications à l'étude des récepteurs oculaires et à l'hybridation in situ

....#1990-30

DENIS P, ELENA PP, NORDMANN JP, LAPALUS P, SARAUX H

Séminaires Ophtalmologiques IPSEN, Royaumont - France 1990

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialized and intact rabbit eye

....#1989-29

FREDJ-REYGROBELLET D, ELENA PP, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P

Curr. Eye Res. 1989; 8: 1141-1152

Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme.#1989-28
Implications fonctionnelles

DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, LAPALUS P
 Bull. Soc. Ophtalmol. Fr. (France) 1989; 89: 807-810

Récepteurs bêta-adrenergiques vasculaires rétiniens chez l'homme#1989-27

DENIS P, **ELENA PP**
 Ophtalmologie (France) 1989; 3: 62-64



Dopamine receptors in rabbit and rat eye: characterization and localization of DA1 and DA2 binding sites#1989-26

ELENA PP, DENIS P, KOSINA-BOIX M, LAPALUS P
 Curr. Eye Res. 1989; 8: 75-83

Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography#1989-25

ELENA PP, KOSINA-BOIX M, DENIS P, MOULIN G, LAPALUS P
 Ophthalmic Res. 1989; 21: 309-314



Localisation of angiotensin-converting enzyme (ACE) in rat ciliary process by autoradiography and immunocytochemistry#1989-24

LALIBERTE F, **ELENA PP**, LALIBERTE MF, LAPALUS P, CHEVILLARD C
 AER meeting 1989; Montpellier - France, Doc. Ophthalmol. 1990; 76: 194-195, abstract No. 167

Beta-adrenergic receptors in human eye sections#1989-23

ELENA PP, DENIS P, LAROCHE L, and LAPALUS P
 AER meeting 1989; Montpellier - France, Doc. Ophthalmol. 1990; 76: 194, abstract No. 166

Autoradiographic localization of vasoactive intestinal peptide binding sites in albino rabbit and rat eye#1989-22

DENIS P, DUSSAILLANT M, NORDMANN JP, **ELENA PP**, ROSTENE W, SARAUX H
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 159-160, abstract No. 104

Autoradiographic localisation of insulin receptors in the human eye#1989-21

ELENA PP, DENIS P, LE MARCHAND-BRUSTEL Y, LAPALUS P
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 158-159, abstract No. 102

Pharmacokinetics of topically-administered aldose reductase inhibitor (E-0722) on pigmented rabbit eye#1989-20

LAPALUS P, FREDJ-REYGROBELLET D, **ELENA PP**
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 129-130, abstract No. 45

Pharmacokinetic and autoradiographic studies of basic fibroblast growth factor on de-epithelialised and intact rabbit eye#1989-19

FREDJ-REYGROBELLET D, **ELENA PP**, MOENNER M, BAUDOUIN C, ETTAICHE M, BARRITAULT D, LAPALUS P
 AER meeting 1989, Montpellier - France, Doc. Ophthalmol. 1990; 76: 111, abstract No. 13

Piribedil and retinal dopaminergic binding sites#1989-18

LAPALUS P, **ELENA PP**, DENIS P, FREDJ-REYGROBELLET D
 World Congress of Neurology 1989, New Dehli – India

Localisation autoradiographique des récepteurs dopaminergiques rétiniens chez l'homme.#1989-17
Implications fonctionnelles

DENIS P, NORDMANN JP, **ELENA PP**, LAROCHE L, LAPALUS P
 SFO meeting 1989, Paris – France

Neurotransmitters and intraocular pressure#1989-16

LAPALUS P, **ELENA PP**
 Fundam. Clin. Pharmacol. (France) 1988; 2: 305-325

Autoradiographic localization of beta-adrenergic binding sites in human blood retinal vessels#1988-15

ELENA PP, DENIS P, LAPALUS P
 ISER meeting 1988, San Francisco, CA – USA

Autoradiographic characterization of D-1 and D-2 receptors in rat, rabbit and human eyes#1988-14

ELENA PP, DENIS P, LAPALUS P
 ISER meeting 1988, San Francisco, CA – USA

Autoradiographic localization of β -adrenergic receptors in rabbit eye

....#1987-13

**ELENA PP** (a), KOSINA-BOIX M (b), MOULIN G (a), LAPALUS P (b)

Invest. Ophthalmol. Vis. Sci. 1987; 28: 1436-1441

(a) Laboratoires DULCIS ALLERGAN, Monaco - (b) the Laboratoire de Pharmacologie Faculte de Medecine, Nice, France

Dopamine DA1 receptors in the eye: characterization and localization of ^{125}I -SCH 23982 binding sites

....#1987-12

ELENA PP, KOSINA-BOIX M, LAPALUS P

AER meeting 1987, Leuven – Belgium

Effects of a new anti-allergic agent: the magnesium salt of N-Acetyl-Aspartyl-Glutamic Acid on experimental allergic inflammation of the rabbit eye

....#1986-11

LAPALUS P, MOULIN G, BAYER V, FREDJ-REYGROBELLET D, **ELENA PP**

Curr. Eye Res. 1986; 5: 517-522

Monoclonal antibodies to human amnion recognize different components of the rabbit eye

....#1986-10

HSI BL, FREDJ-REYGROBELLET D, YEH CJG, **ELENA PP**, MOULIN G, LAPALUS P

Invest. Ophthalmol. Vis. Sci. 1986; 27: 620-622

**Système alpha-adrénergique et pression intra-oculaire**

....#1986-9

LAPALUS P, ELENA PP

Rencontres Internationales de Chimie Thérapeutique, Clermont-Ferrand - France 1986

Autoradiographic localization of β -adrenergic receptors in rabbit eye

....#1986-8

ELENA PP, KOSINA-BOIX M, MOULIN G, LAPALUS P

AER meeting 1986, Oxford – UK

Embryological studies of rabbit eye by using monoclonal antibodies

....#1985-7

FREDJ-REYGROBELLET D, HSI BL, MOULIN G, YEH CJG, **ELENA PP**, and LAPALUS P

AER meeting 1985, Leyzin - Switzerland, p 61 abstract No. 73

Alpha-adrenoceptors in rabbit iris-ciliary-body (ICB) membranes: characterization and localization with ^3H -clonidine

....#1985-6

ELENA PP, PALTRINIERI P, MOULIN G, FREDJ-REYGROBELLET D, LAPALUS P

AER meeting 1985, Leyzin - Switzerland, p 5

Pharmacological characteristics of β -adrenergic-sensitive adenylate cyclase in non-pigmented and pigmented cells of bovine ciliary process

....#1984-5

ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P

Curr. Eye Res. 1984; 3: 1383-1389

Characterization of β -adrenergic receptors in bovine pigmented ciliary processes

....#1984-4

ELENA PP, MOULIN G, LAPALUS P

Curr. Eye Res. 1984; 3: 743-750

Etude cinétique d'un anti-allergique, le ^{14}C -T86 en instillation chez le lapin albinos

....#1984-3

LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, LAPALUS F

J. Biophys. Med. Nucl. 1984; 8: 195-198

Etude cinétique d'un anti-allergique, le ^{14}C -T86, en instillation chez le lapin albinos

....#1984-2

LAPALUS P, MOULIN G, BAYER V, **ELENA PP**, NICOLAS C, LAPALUS F

Congrès de Médecine Nucléaire de Langue Française, Nice - France 1984

Adenylate cyclase activity in non-pigmented (NPE) and in pigmented (PE) cells of bovine ciliary process

....#1984-1

ELENA PP, FREDJ-REYGROBELLET D, MOULIN G, LAPALUS P

ISER meeting 1984, Alicante - Spain, p 95

Wound healing of different epithelia in albino rabbit eye anterior segment

....#1984-232

FREDJ-REYGROBELLET D, MOULIN G, **ELENA PP**, LAPALUS P

ISER meeting 1984, Alicante - Spain, p.95

ABBREVIATIONS

ARVO	Association for Research in Vision and Ophthalmology
ATERET	Association Tunisienne d'Etude et de Recherche sur les Éléments Trace
ECLSO	European Contact Lens Society of Ophthalmologists
EVER	European Vision and Eye Research
IGS	International Glaucoma Symposium
ISECOPP	International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics
ISOPT	International Symposium on Ocular Pharmacology and Therapeutics
MCLOSA	Medical Contact Lens and Ocular Surface Association
SAFIR	Société de l'Association Française des Implants et de la chirurgie Réfractive
SFERETE	Société Francophone d'Etude et de Recherche sur les Éléments Traces Toxiques et Essentiels
SFO	Société Française d'Ophtalmologie
SFVB	Société Francophone Vitamines et Biofacteurs